ARGX vs. GILD, MRNA, BIIB, BNTX, NBIX, TECH, QGEN, PCVX, RVMD, and RGEN
Should you be buying argenx stock or one of its competitors? The main competitors of argenx include Gilead Sciences (GILD), Moderna (MRNA), Biogen (BIIB), BioNTech (BNTX), Neurocrine Biosciences (NBIX), Bio-Techne (TECH), Qiagen (QGEN), Vaxcyte (PCVX), Revolution Medicines (RVMD), and Repligen (RGEN). These companies are all part of the "biological products, except diagnostic" industry.
argenx (NASDAQ:ARGX) and Gilead Sciences (NASDAQ:GILD) are both large-cap medical companies, but which is the superior investment? We will compare the two businesses based on the strength of their valuation, analyst recommendations, community ranking, media sentiment, profitability, institutional ownership, risk, dividends and earnings.
60.3% of argenx shares are held by institutional investors. Comparatively, 83.7% of Gilead Sciences shares are held by institutional investors. 2.4% of argenx shares are held by insiders. Comparatively, 0.2% of Gilead Sciences shares are held by insiders. Strong institutional ownership is an indication that hedge funds, large money managers and endowments believe a company will outperform the market over the long term.
argenx has a beta of 0.64, indicating that its share price is 36% less volatile than the S&P 500. Comparatively, Gilead Sciences has a beta of 0.18, indicating that its share price is 82% less volatile than the S&P 500.
argenx presently has a consensus target price of $539.05, suggesting a potential upside of 9.02%. Gilead Sciences has a consensus target price of $81.81, suggesting a potential upside of 6.24%. Given argenx's stronger consensus rating and higher possible upside, equities analysts clearly believe argenx is more favorable than Gilead Sciences.
Gilead Sciences received 1829 more outperform votes than argenx when rated by MarketBeat users. Likewise, 77.28% of users gave Gilead Sciences an outperform vote while only 66.52% of users gave argenx an outperform vote.
In the previous week, argenx had 12 more articles in the media than Gilead Sciences. MarketBeat recorded 39 mentions for argenx and 27 mentions for Gilead Sciences. Gilead Sciences' average media sentiment score of 0.60 beat argenx's score of 0.57 indicating that Gilead Sciences is being referred to more favorably in the news media.
Gilead Sciences has higher revenue and earnings than argenx. argenx is trading at a lower price-to-earnings ratio than Gilead Sciences, indicating that it is currently the more affordable of the two stocks.
Gilead Sciences has a net margin of 1.76% compared to argenx's net margin of -22.58%. Gilead Sciences' return on equity of 24.34% beat argenx's return on equity.
Summary
Gilead Sciences beats argenx on 11 of the 19 factors compared between the two stocks.
Get argenx News Delivered to You Automatically
Sign up to receive the latest news and ratings for ARGX and its competitors with MarketBeat's FREE daily newsletter.
This chart shows the number of new MarketBeat users adding ARGX and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period.
This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.
Related Companies and Tools
